Clinical Trial Update: Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) [Phase 3]

View source ↗

Summary

Phase 3 trial update showing completion of a study evaluating an investigational compound's effect on the tolerability of extended-release niacin in hypercholes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Niaspan (extended-release niacin) (nicotinic acid)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesteremia, Hyperlipidemia | Phase 3 | Status: COMPLETED